背景:本研究旨在探讨益生菌罗伊氏乳杆菌在治疗和预防乳腺癌中的作用。
方法:在II组中使用氯化镉(Cd)(2mg/kg)诱发乳腺癌。他莫昔芬给予组III。第IV组用罗伊氏乳杆菌处理。V组用Cd治疗1个月,分为3个亚组,包括VA,VB,和VC用他莫昔芬治疗,罗伊氏乳杆菌,还有他莫昔芬+罗伊氏乳杆菌,分别。
结果:TNF-α水平明显升高(40.9±4.2pg/mL),IL-6(28.0±1.5pg/mL),IL-10(60.2±2.0pg/mL),IFN-γ(60.2±2.0pg/mL),ALAT(167.2±6.2U/l),ASAT(451.6±13.9U/l),在Cd组中观察到MDA(553.8±19.6U/l)。相比之下,显著降低TNF-α水平(18.0±1.1pg/mL),IL-6(9.4±0.4pg/mL),IL-10(20.8±1.1pg/mL),IFN-γ(20.8±1.1pg/mL),ALAT(85.2±3.6U/l),ASAT(185±6.9U/l),在CdTamLR组中观察到MDA(246.0±7.5U/l)。Cd组肝组织病理学表现为出血和导管畸变。然而,在治疗组中观察到轻度炎症和更健康的分支导管。此外,肾脏对照组显示正常的肾小球毛簇,Cd组的慢性炎症,和相对健康的肾小球轻度炎症治疗组。
结论:因此,目前的研究结果认可了益生菌罗伊氏乳杆菌的预防和抗癌作用.
BACKGROUND: The current study aimed to investigate the role of probiotic Lactobacillus reuteri for the treatment and prevention of breast cancer.
METHODS: Breast cancer was induced by using Cadmium Chloride (Cd) (2 mg/kg) in group II. Tamoxifen was administered to group III. Group IV was treated with Lactobacillus reuteri. Group V was treated with Cd for one month and divided into three subgroups including VA, VB, and VC which were treated with tamoxifen, Lactobacillus reuteri, and tamoxifen + Lactobacillus reuteri, respectively.
RESULTS: Significantly higher levels of TNF-α (40.9 ± 4.2 pg/mL), IL-6 (28.0 ± 1.5 pg/mL), IL-10 (60.2 ± 2.0 pg/mL), IFN-γ (60.2 ± 2.0 pg/mL), ALAT (167.2 ± 6.2 U/l), ASAT (451.6 ± 13.9 U/l), and MDA (553.8 ± 19.6 U/l) was observed in Cd group. In comparison, significantly lower levels of TNF-α (18.0 ± 1.1 pg/mL), IL-6 (9.4 ± 0.4 pg/mL), IL-10 (20.8 ± 1.1 pg/mL), IFN-γ (20.8 ± 1.1 pg/mL), ALAT (85.2 ± 3.6 U/l), ASAT (185 ± 6.9 U/l), and MDA (246.0 ± 7.5 U/l) were observed in group Cd + Tam + LR. Liver histopathology of the Cd group showed hemorrhage and ductal aberrations. However, mild inflammation and healthier branched ducts were observed in treatment groups. Furthermore, the renal control group showed normal glomerular tufts, chronic inflammation from the Cd group, and relatively healthier glomerulus with mild inflammation in treatment groups.
CONCLUSIONS: Hence, the preventive and anticancerous role of probiotic Lactobacillus reuteri is endorsed by the findings of the current study.